These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 38280033)

  • 61. A novel strategy to increase the therapeutic potency of GBM chemotherapy via altering parenchymal/cerebral spinal fluid clearance rate.
    Umlauf BJ; Frampton G; Cooper A; Greene HF
    J Control Release; 2023 Dec; 364():195-205. PubMed ID: 37865172
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.
    Hersh DS; Harder BG; Roos A; Peng S; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
    Neuro Oncol; 2018 Sep; 20(10):1321-1330. PubMed ID: 29897522
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Up-Regulation of Cyclooxygenase-2 (COX-2) Expression by Temozolomide (TMZ) in Human Glioblastoma (GBM) Cell Lines.
    Lombardi F; Augello FR; Artone S; Gugu MK; Cifone MG; Cinque B; Palumbo P
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163465
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Low MGMT digital expression is associated with a better outcome of IDH1 wildtype glioblastomas treated with temozolomide.
    Gomes I; Moreno DA; Dos Reis MB; da Silva LS; Leal LF; Gonçalves GM; Pereira CA; Oliveira MA; de Medeiros Matsushita M; Reis RM
    J Neurooncol; 2021 Jan; 151(2):135-144. PubMed ID: 33400009
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Zinc enhances temozolomide cytotoxicity in glioblastoma multiforme model systems.
    Toren A; Pismenyuk T; Yalon M; Freedman S; Simon AJ; Fisher T; Moshe I; Reichardt JK; Constantini S; Mardor Y; Last D; Guez D; Daniels D; Assoulin M; Mehrian-Shai R
    Oncotarget; 2016 Nov; 7(46):74860-74871. PubMed ID: 27556862
    [TBL] [Abstract][Full Text] [Related]  

  • 66. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 67. MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy.
    Melguizo C; Prados J; González B; Ortiz R; Concha A; Alvarez PJ; Madeddu R; Perazzoli G; Oliver JA; López R; Rodríguez-Serrano F; Aránega A
    J Transl Med; 2012 Dec; 10():250. PubMed ID: 23245659
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo.
    Yu Z; Zhao G; Xie G; Zhao L; Chen Y; Yu H; Zhang Z; Li C; Li Y
    Oncotarget; 2015 Oct; 6(32):32930-43. PubMed ID: 26431379
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
    Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
    Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Alkylaminophenol and GPR17 Agonist for Glioblastoma Therapy: A Combinational Approach for Enhanced Cell Death Activity.
    Doan P; Nguyen P; Murugesan A; Candeias NR; Yli-Harja O; Kandhavelu M
    Cells; 2021 Aug; 10(8):. PubMed ID: 34440745
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Tetra-O-methyl nordihydroguaiaretic acid, an inhibitor of Sp1-mediated survivin transcription, induces apoptosis and acts synergistically with chemo-radiotherapy in glioblastoma cells.
    Castro-Gamero AM; Borges KS; Moreno DA; Suazo VK; Fujinami MM; de Paula Gomes Queiroz R; de Oliveira HF; Carlotti CG; Scrideli CA; Tone LG
    Invest New Drugs; 2013 Aug; 31(4):858-70. PubMed ID: 23299390
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Downregulation of SNRPG induces cell cycle arrest and sensitizes human glioblastoma cells to temozolomide by targeting Myc through a p53-dependent signaling pathway.
    Lan Y; Lou J; Hu J; Yu Z; Lyu W; Zhang B
    Cancer Biol Med; 2020 Feb; 17(1):112-131. PubMed ID: 32296580
    [No Abstract]   [Full Text] [Related]  

  • 73. Thioridazine inhibits autophagy and sensitizes glioblastoma cells to temozolomide.
    Johannessen TC; Hasan-Olive MM; Zhu H; Denisova O; Grudic A; Latif MA; Saed H; Varughese JK; Røsland GV; Yang N; Sundstrøm T; Nordal A; Tronstad KJ; Wang J; Lund-Johansen M; Simonsen A; Janji B; Westermarck J; Bjerkvig R; Prestegarden L
    Int J Cancer; 2019 Apr; 144(7):1735-1745. PubMed ID: 30289977
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Oncolytic Newcastle Disease Virus Co-Delivered with Modified PLGA Nanoparticles Encapsulating Temozolomide against Glioblastoma Cells: Developing an Effective Treatment Strategy.
    Kadhim ZA; Sulaiman GM; Al-Shammari AM; Khan RA; Al Rugaie O; Mohammed HA
    Molecules; 2022 Sep; 27(18):. PubMed ID: 36144488
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Synthesis and Characterization of a Series of Temozolomide Esters and Its Anti-glioma Study.
    Yu Y; Wang L; Han J; Wang A; Chu L; Xi X; Kan R; Sha C; Sun K
    J Pharm Sci; 2021 Oct; 110(10):3431-3438. PubMed ID: 34147518
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Piperlongumine-inhibited TRIM14 signaling sensitizes glioblastoma cells to temozolomide treatment.
    Kuo YY; Ho KH; Shih CM; Chen PH; Liu AJ; Chen KC
    Life Sci; 2022 Nov; 309():121023. PubMed ID: 36202175
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A co-culture model with brain tumor-specific bioluminescence demonstrates astrocyte-induced drug resistance in glioblastoma.
    Yang N; Yan T; Zhu H; Liang X; Leiss L; Sakariassen PØ; Skaftnesmo KO; Huang B; Costea DE; Enger PØ; Li X; Wang J
    J Transl Med; 2014 Oct; 12():278. PubMed ID: 25280402
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Dual inhibition of PFKFB3 and VEGF normalizes tumor vasculature, reduces lactate production, and improves chemotherapy in glioblastoma: insights from protein expression profiling and MRI.
    Zhang J; Xue W; Xu K; Yi L; Guo Y; Xie T; Tong H; Zhou B; Wang S; Li Q; Liu H; Chen X; Fang J; Zhang W
    Theranostics; 2020; 10(16):7245-7259. PubMed ID: 32641990
    [No Abstract]   [Full Text] [Related]  

  • 79. Targeting Glioma Initiating Cells with A combined therapy of cannabinoids and temozolomide.
    López-Valero I; Saiz-Ladera C; Torres S; Hernández-Tiedra S; García-Taboada E; Rodríguez-Fornés F; Barba M; Dávila D; Salvador-Tormo N; Guzmán M; Sepúlveda JM; Sánchez-Gómez P; Lorente M; Velasco G
    Biochem Pharmacol; 2018 Nov; 157():266-274. PubMed ID: 30195736
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
    Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
    J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.